Introduction
The endothelial differentiation gene-encoded (Edg) G protein-coupled receptors transduce signals from lysophospholipids to cellular proliferation, survival, and diverse cytoskeleton-based functions (Tigyi and Goetzl 2002; Chun et al., 2002) . LPA 1 , LPA 2 and LPA 3 bind and are activated by lysophosphatidic acid (LPA), whereas S1P 1 to S1P 5 are similarly specific for sphingosine 1-phosphate (S1P). One or more LPA or S1P receptors are overexpressed by most human cancer cells, especially those which are highly responsive to sex hormones such as prostate and ovarian cancers Xie et al., 2002) . Human prostate cancer cells overexpress LPA 1 and LPA 2 , but not LPA 3 , relative to nonmalignant precursors (Xie et al., 2002) . LPA stimulates extracellular signal-regulated kinases (ERKs) and enhances phosphorylation of focal adhesion kinase in prostate cancer cells (Xie et al., 2002) . Most ovarian cancer cells overexpress LPA 2 and LPA 3 relative to normal ovarian surface epithelial cells and other ovarian cells (Goetzl et al., 1999; Fang et al., 2002; Fujita et al., 2003; Xu et al., 2003) . LPA evokes ovarian cancer cell migration, proliferation and release of some endogenous polypeptide growth factors (Mills et al., 1990; Goetzl et al., 1999; Mills et al., 2002) . LPA 4 , a recently identified adenosine GPCR subfamily-related receptor for LPA, is also highly expressed in the ovary, but its distribution in ovarian cancer is not known (Noguchi et al., 2003) . Prostate and ovarian cancers, but not other human cancers, also generate larger quantities of LPA than nonmalignant cells of the same type through pathways stimulated by mitogens and numerous other factors Xie et al., 2002) . The prominent production and effects of LPA in most ovarian and prostate cancers have suggested that this is an autocrine system that promotes growth and invasion in such cancers.
The stimulation by LPA of prostate and ovarian cancer cell proliferation is mediated both directly through a ras-ERK signaling pathway and by enhanced release of several endogenous protein growth factors (GFs), including IGF-II and vascular endothelial growth factor (VEGF) (Goetzl et al., 1999; Hu et al., 2001) . Such endogenous GFs mediate up to 80% of the stimulation of cellular proliferation by LPA (Goetzl et al., 1999) . To more directly investigate roles of the LPA-LPA 2 receptor axis in upregulation of protein GFs, transgenic (TG) mice were developed which overexpress human LPA 2 in ovarian interstitial tissues. Ovarian cells from TG mice secrete greater amounts of VEGF and urokinase-type plasminogen activator (uPA), which both are functional markers for ovarian cancer, express more VEGF receptors, and have a lower level of type 2 PA inhibitor than non-TG mouse ovarian cells. These data suggest that the LPA-LPA 2 axis alone is capable of upregulating ovarian activity of protein growth factor systems considered to be functional markers of ovarian cancer. It remains to be proven whether these elevated levels of growth factors create an ovarian precancerous state, which may be more than normally susceptible to development of cancer.
Results
High tissue-selective expression of human LPA 2 in TG mouse ovaries TG mice were generated with both human wild-type LPA 2 and a human mutant LPA 2 , which has a Cterminal cytoplasmic tail 35 amino acids longer than that of the native LPA 2 and transduces greater signals from LPA than wild-type LPA 2 . Most data are from the mutant LPA 2 TG mice, as they were more prolific breeders, but similar results are presented in summary for the wild-type LPA 2 TG mice. The expression of human LPA 2 in the tissues of whole mouse ovaries was examined by Taqman real-time reverse transcription-polymerase chain reaction (RT-PCR) and Western blot analyses. Human mutant LPA 2 mRNA in ovaries from 20 TG mice of two different founder lines was 5-60-fold higher than in OVCAR and 36M2 human cultured ovarian cancer cells, which had the highest levels of the three lines examined, whereas no human LPA 2 expression was detected in non-TG ovaries (Figure 1 ). The mean ratio of human mutant LPA 2 mRNA to human wild-type LPA 2 mRNA in whole ovaries of the two TG lines was 0.7. Evaluation of the tissue specificity of expression of mutant LPA 2 in TG mice showed levels of LPA 2 mRNA in ovaries 4-26-fold higher than that of any other tissues in TG mice (Figure 2 ).
LPA interacts with three members of the Edg (endothelial differentiation gene) subfamily of G protein-coupled receptors, including LPA 1 (also known as Edg-2), LPA 2 (Edg-4), and LPA 3 (Edg-7). The mean relative normalized levels of mRNA encoding endogenous mouse LPA 1 , LPA 2 , and LPA 3 in non-TG and human mutant LPA 2 TG ovaries were 0.81 and 0.91; 0.79 and 0.85; and 0.82 and 0.52, respectively. The decrease in the expression of endogenous mouse LPA 3 (Edg-7) (Po0.01) in TG ovaries was the only significant alteration and is quantitatively minor compared to the increase in TG LPA 2 . The results were similar for several human wild-type LPA 2 TG mice. Thus, differences in the responses of non-TG and TG ovaries to LPA are unlikely to be attributed to transgene-induced changes in levels of endogenous LPA Rs.
Western immunoblots of ovarian proteins showed levels of approximately 55 kDa LPA 2 protein (Goetzl et al., 1999) in five TG ovaries of two different founder lines of human mutant LPA 2 TG mice, which were higher than in non-TG mice (Figure 3 ). The anti-LPA 2 antibody used recognizes both human and mouse LPA 2 (Goetzl et al., 1999) Ovary Adrenal gland heart lung spleen uterus Figure 2 Tissue-specific distribution of human LPA 2 in TG mice. RNAs isolated from TG mouse ovary, adrenal glands, heart, lung, spleen and uterus were examined for their levels of human LPA 2 mRNA normalized to that of HPRT. All the normalized levels of LPA 2 mRNA in nonovarian tissues were compared to that of TG ovary, which was set at 1. Immunohistochemical analyses of ovarian tissues were performed using the same anti-LPA 2 mouse monoclonal antibody as in Western blot analyses. The staining of LPA 2 proteins was detected most strongly among the sex cord-stromal regions of the TG ovaries, with only very light staining in the surface epithelium as predicted from the specificity of the targeting promoter (Figure 4) . A strikingly higher level of overall expression of human LPA 2 was apparent in the stromal region, granulosa cells and luteinized cells of TG ovaries. In contrast, only a background level of staining is seen in the stromal region of non-TG ovaries (Figure 4 ). The human mutant LPA 2 (Edg-4) TG mice were expected to have high levels of LPA 2 expression in the sex cordstromal compartment of their ovaries based on the known targeting properties of mouse a-inhibin large promoter (Kananen et al., 1995; Hsu et al., 1996) . There are also consistently many more prominent nodules composed of luteinized cells observed in the TG ovaries than in age-matched wild-type ovaries.
Differential enhancement of VEGF-A, but not VEGF-B, levels in human LPA 2 TG mouse ovaries
Most ovarian cancers express elevated levels of vascular endothelial growth factor (VEGF) mRNA, and the plasma concentration of VEGF is increased in many ovarian cancer patients (Fujimoto et al., 1998; Hazelton et al., 1999; Zebrowski et al., 1999; Hu et al., 2001) . As VEGF has essential roles in ovarian tumorigenesis, angiogenesis and vascular permeability, we evaluated the expression of VEGF-A and VEGF-B mRNAs in our human LPA 2 TG mice by Taqman real-time RT-PCR. A total of 20 RNA samples from human mutant LPA 2 TG ovaries of two different founder lines and seven RNA pools from 2 to 10 control non-TG ovaries each were examined for their expression of mouse VEGF-A and VEGF-B. The mean VEGF mRNA level in TG ovaries was 2.5 (range ¼ 1.2-4.4) compared to 1.03 in non-TG ( Figure 5 ), and 100% of the TG ovarian RNA samples exhibited a higher level of VEGF mRNA expression than the average level of wild-type ovary mRNA. In contrast, there was no significant difference in VEGF-B mRNA levels between wild-type and TG ovarian samples ( Figure 5 ).
There are five isoforms for VEGF-A resulting from alternative splicing of the same gene: VEGF 120 , VEGF 144 , VEGF 164 , VEGF 188 and VEGF 205 (Neufeld et al., 1996; Shima et al., 1996; Tober et al., 1998) . Only the three most abundant isoforms, VEGF 120 , VEGF 164 , and VEGF 188 , were detected in the seven pools of RNA from non-TG ovaries and RNA from 20 human mutant TG ovaries, but the level of each was higher in TG ovaries than in non-TG ovaries ( Figure 6 ). VEGF 120 , VEGF 164 and VEGF 188 mRNA levels were increased by Real-time RT-PCR quantification of VEGF isoforms in ovarian tissues. VEGF-A is significantly upregulated in human LPA 2 TG mouse ovaries compared to wild-type mouse ovaries. A Student's t-test analysis revealed P ¼ 4 Â 10 À6 (Po0.000005) for the difference in VEGF-A mRNA between wild-type and human LPA 2 TG mouse ovaries. VEGF-B is no different in TG than in wild-type ovaries (P ¼ 0.32). All the results are normalized to HPRT. Each individual value is from studies performed in triplicate at least two times, and the horizontal line in each column is the mean for that group Figure 4 Immunohistochemical localization of human LPA 2 proteins in TG and wild-type ovaries. Fresh-frozen cryosections were incubated with 20-200 ng/ml of mouse anti-LPA 2 monoclonal antibody and developed with anti-mouse IgG antibody coupled to horseradish peroxidase means of 55, 80 and 56%, respectively, in TG compared to non-TG ovaries. Among the three isoforms, 15 out of 20 TG ovaries expressed higher levels of VEGF 120 , VEGF 164 and VEGF 188 than the averages for non-TG ovaries. Results were similar for the few human wildtype LPA 2 TG mice examined in the same protocol.
Western immunoblotting and immunohistochemistry with a rabbit anti-human recombinant VEGF 165 , which also recognizes mouse VEGF, were conducted to quantify and localize VEGF protein expression in TG and non-TG ovaries. Six TG ovaries expressed at least 2.5-fold higher level (range ¼ 2.5-14.7-fold) of the 34 kDa VEGF protein than non-TG ovaries, consistent with what was seen for real-time RT-PCR quantification of VEGF mRNA (Figure 7 ). With the same anti-VEGF antibody, the overall level of VEGF protein in the TG ovaries was much higher in all compartments than in the non-TG ovaries. Murine VEGF protein staining was detected most strongly among the sex cordstromal regions, including granulosa cells, luteinized cells and the epithelium of fallopian tubes, in TG as well as non-TG ovaries, with no staining in the surface epithelium (Figure 8 ). No staining was observed in the negative control without primary VEGF antibody (data not shown). Findings were similar for a few human wildtype LPA 2 TG mouse ovaries. Thus, the distribution of VEGF is similar to that of TG LPA 2 .
Augmentation of the levels of VEGF R1 and VEGF R2 in human LPA 2 TG mouse ovaries
The basic biological activities of VEGF-A and VEGF-B are mediated principally by the VEGF R2 tyrosine kinase receptor, although both VEGF R1 (Flt-1, fmslike tyrosine kinase receptor) and VEGF R2 (flk-1, fetal liver kinase) bind VEGF-A and VEGF-B (Seetharam et al., 1995; Gerber et al., 1998; Neufeld et al., 1999) . Six of 20 human mutant TG mouse ovaries exhibited a level of VEGF R1 mRNA more than twofold higher than those of non-TG control mouse ovaries (Figure 9 ). In contrast, only two out of 20 TG mouse ovaries expressed levels of VEGF R2 mRNA more than twofold higher than non-TG ovaries (Figure 9 ). In all, 12 out of 20 (60%) TG ovaries exhibited higher levels of VEGF R1 and VEGF R2 than the average for non-TG ovaries. Thus, VEGF Rs as well as VEGF-A are upregulated in LPA 2 TG ovaries.
uPA is increased and type 2 PA inhibitor is decreased in human LPA 2 TG mouse ovaries uPA is another functional marker for ovarian cancer that was quantified in ovaries of LPA 2 TG mice. There were significantly higher levels of uPA mRNA in human mutant TG than non-TG mouse ovaries (Table 1) . In all, 13 out of 20 TG mice (65%) had at least twofold higher levels of uPA mRNA than those of non-TG controls, with a mean twofold increase over the non-TG level; 19 out of 20 (95%) TG ovarian RNA samples Figure 6 Higher levels of mRNA encoding the VEGF 120 , VEGF 164 and VEGF 188 isoforms of mouse VEGF-A in human LPA 2 TG than wild-type control ovaries. The levels of VEGF isoform mRNA were quantified by real-time RT-PCR, and results were normalized to a house keeping gene and standardized relative to the level of mRNA in one wild-type mouse ovary that was included in all the experiments. Each individual value is from studies performed at least in triplicate at least two times. A twosample Student's t-test revealed significant differences for all three isoforms between levels in wild-type and human LPA 2 TG mouse ovaries (* ¼ Po0.005 for VEGF 120 , VEGF 188 and ** ¼ Po0.001 for VEGF 164 ) Figure 7 Immunodetection of VEGF-A proteins in human LPA 2 TG and wild-type mouse ovaries. Ovarian proteins (10 mg) were resolved in a 12.5% SDS-polyacrylamide gel and detected with 2.86 mg/ml of rabbit polyclonal antibody to VEGF. An approximately 34 kDa band corresponding to VEGF proteins is observed in wild-type and TG mouse ovaries. MW ¼ molecular weight marker; Wt ¼ wild-type mouse ovary and 1-6 ¼ LPA 2 TG mouse ovaries Figure 8 Immunohistochemical localization of VEGF proteins in ovaries of human LPA 2 TG mice and wild-type mice. The ovarian sections were incubated with 1.3 mg/ml of rabbit polyclonal antibody to VEGF. VEGF proteins were observed in sex cordstromal regions, such as granulosa cells and luteinized cells in both human LPA 2 TG and wild-type mice. The level of ovarian VEGF staining is significantly higher in ovaries of human LPA 2 TG mice than wild-type mice demonstrated a higher level of uPA expression than the average level of non-TG ovary RNA. Expressions of the uPA receptor and of tissue-type PA were no different in human mutant LPA 2 TG mouse ovaries than in non-TG ovaries (Table 1) . However, expression of the type 2 PA inhibitor was significantly lower in TG ovaries than non-TG ovaries, without any alterations in the level of type 1 PA inhibitor (Table 1) . Thus, two distinct families of functional ovarian tumor markers are abnormally expressed in human LPA 2 TG mouse ovaries. That upregulation of mRNA consequently increases the level of ovarian secretion of a growth factor was proven by measuring VEGF protein and uPA activity in supernatant media from cultures of mutant LPA 2 TG mouse and non-TG mouse ovarian cells (Table 2) . Levels of both mediators were approximately twofold higher in media from cultures of TG ovarian cells than non-TG ovarian cells.
Discussion
The production of large amounts of LPA and concurrently heightened expression of LPA 2 and LPA 3 GPCRs by ovarian cancer cells establishes an autocrine loop postulated to enhance cellular proliferation and suppress apoptosis (Mills et al., 1990; Goetzl et al., 1999; Hu et al., 2001; Fang et al., 2002; Mills et al., 2002) . The LPA-LPA 2/3 GPCR loop also apparently has the capacity to promote cellular survival, migration and spread of ovarian cancer (Zhu et al., 2001; Xu, 2002; Xu et al., 2003) . LPA production and expression of one or more LPA GPCRs also have been documented in other cancers and in some normal physiological responses (Tokumura, 2002; Dolezalova et al., 2003) . Some of these effects of LPA-LPA R loops in ovarian cancer and other cancers are mediated by increased secretion of protein growth factors, enhanced expression of their receptors, and/or altered levels of regulatory proteins, which amplifies the primary effects of the augmented lysophospholipid system. The present application of ovarian-targeted overexpression of LPA 2 documents the ability of one component of the LPA-LPA 2 GPCR loop to upregulate the production and/or recognition of two potent endogenous protein growth factors, which are thought to be involved in the pathogenesis of human ovarian cancer (Mills et al., 1990; Goetzl et al., 1999; Hu et al., 2001; Fang et al., 2002; Mills et al., 2002) .
LPA 2 clearly is highly expressed in TG mouse ovaries with both tissue selectivity of targeting and relative levels approximately 10-fold higher than in human ovarian cancer cells (Figures 1 and 2 ). The LPA 2 protein level in both mutant and wild-type LPA 2 TG lines also is much higher in TG then in non-TG ovaries, with a stromal intraovarian distribution expected for the targeting a-inhibin promoter (Figures 3 and 4) . The resultant increase in VEGF-A, but not VEGF-B, shows isotype specificity and often is accompanied by elevation of VEGF receptors ( Figures 5, 6 and 9) typical of human ovarian cancer (Boocock et al., 1995; Luo et al., 1998; Orre and Rogers, 1999; Stimpfl et al., 2002) . All the 20 mutant LPA 2 TG ovaries exhibited higher levels Wild-type Transgenic Figure 9 Real-time RT-PCR quantification of levels of expression of VEGF R1 and VEGF R2 mRNA in human LPA 2 TG and wildtype mouse ovaries. Each value is from studies performed in triplicate at least two times and was normalized to HPRT before those of TG LPA 2 mice were compared to those of concurrently evaluated wild-type mice. Differences in the levels of VEGF R1 and VEGF R2 mRNAs between TG LPA 2 mouse and wild-type mouse ovaries were calculated by a two-sample Student's t-test; Po0.01(*) for both VEGF R1 and R2 The levels of mRNA encoding uPA, tPA, uPAR, PAI-1 and PAI-2 in ovaries of LPA 2 TG and wild-type mice were quantified by real-time RT-PCR. uPA upregulation (1.7-fold increase in TG ovaries) and PAI-2 downregulation (47% decrease in TG ovaries) in human LPA 2 TG mouse ovaries, as contrasted with levels in wild-type mouse ovaries; both are significant. All the assays were performed in triplicate at least two times, and were normalized to murine HPRT VEGF ELISA and uPA activity assay were used to measure the levels of VEGF and active uPA in isolated ovarian tissues cultured ex vivo.
The results indicated that production of VEGF protein was 2.4-fold higher, and that of uPA activity 1.7-fold greater in TG ovaries than wild-type ovaries of VEGF-A mRNA than the average level of non-TG ovaries. Among these 20 human LPA 2 TG ovaries, 11 had more than twofold increases and nine showed modest increases in the expression of VEGF with or without heightened levels of VEGF receptors compared to wild-type ovaries. Seven of 20 TG ovaries had high levels of VEGF-A, isoforms of VEGF-A, and VEGF R1 and VEGF R2. Findings were similar for human wildtype LPA 2 TG mouse ovaries, despite earlier demonstrations of in vitro increases in signal transduction by the mutant LPA 2 GPCR . The preferential localization of VEGF in the sex cordstromal region of TG ovaries (Figure 8) suggests that increased activity of the LPA-LPA 2 loop in the interstitium is sufficient to evoke a prominent increase in the VEGF system in the same compartment. Whether this is a function of LPA-LPA 2 activity generating a second interstitial mediator capable of upregulating VEGF or of increased LPA acting directly on the interstitium is a question that will require more detailed analyses of isolated cell populations. That uPA mRNA and activity are elevated, and PAI-2 is suppressed in TG ovaries suggests that the LPA-LPA 2 GPCR system influences transcriptional pathways of multiple protein GFs and GF regulatory proteins (Tables 1 and 2 ). Recent findings have suggested that autotaxin, a lysophospholipase D (lysoPLD) expressed predominantly in tumors Moolenaar, 2002; Umezu-Goto et al., 2002) , may be the predominant source of LPA but its distribution in tumors is still being delineated.
Upregulation of VEGF-A and the VEGF receptors is especially significant as this represents one mechanism for spread of ovarian cancers. The VEGF system both stimulates angiogenesis necessary for tumor survival and increases neovascular permeability, which allows greater fluid transudation and peritoneal invasion of the tumor. Antibodies that block VEGF and soluble VEGF receptor activity suppress ovarian cancer-induced ascites and several aspects of its peritoneal spread in animal models (Mesiano et al., 1998; Yukita et al., 2000; Hu et al., 2002) .
As the observed increase in the function of the LPA-LPA 2 axis in TG mice is sufficient to stimulate VEGF and uPA growth pathways, it is likely that other systems critical for neoplastic behavior will be enhanced as well. Protein kinase B or Akt is stimulated by LPA in many cell types, where it improves cell survival by MEK-and p38 MAP kinase-dependent mechanisms. That LPAevoked Akt is involved in ovarian cancer is further suggested by the findings that LPA pretreatment suppresses paclitaxel-induced increases in caspase 3 activity and inhibition of Akt activation sensitizes human ovarian cancer cells to paclitaxel (Baudhuin et al., 2002) .
The recent demonstration that a tumor cell motilitystimulatory factor, termed autotaxin, is identical to lysoPLD has heightened attention to the self-reinforcing LPC-lysoPLD system in cancer (Moolenaar, 2002; Umezu-Goto et al., 2002) . Increased autocrine or paracrine generation and secretion of LPC and lysoPLD together in tumors vastly augments the generation of LPA, which is the final mediator of increased tumor cell motility for this system Moolenaar, 2002; Umezu-Goto et al., 2002) . It is also probable that LPA will increase levels of lysoPLD as it does PLD (Qi et al., 1998) . Thus, LPA involvement in an augmented LPA-LPA 2 axis of ovarian cancer cells is expected to derive from and also contribute to greater lysoPLD activity and to stimulate tumor cell motility.
That heightened activity of the LPA-LPA 2 system in LPA 2 TG mice does not alone result in frank ovarian malignancy reinforces the hypothesis that this system contributes to carcinogenesis and cancer spread, but is not alone a complete stimulus or promoter. It is presumed that addition of other different susceptibility factors, such as an oncogene, or deletion of a control, such as p53, will promote carcinogenesis. Although interstitial ovarian cancer represents only a small percentage of human cases, this first step was taken because of the efficiency of the a-inhibin promoter and the difficulties of targeting ovarian epithelial cells selectively without introducing artificial elements, such as SV40. It will be important to proceed next to other models, such as an LPA 2 plus LPA 3 transgene with ovarian epithelial localization, combined TG expression of LPA 2 and/or LPA 3 with biochemically heightened systems for local production of LPA, and TG ovarian overexpression of LPA 2 and/or LPA 3 with other susceptibility factors.
Materials and methods

TG mice
Human LPA 2 (Edg-4) TG mice were generated by injecting C57BL/6 oocytes with a minigene consisting of a 1053 bp cDNA encoding human mutant LPA 2 , with a C-terminal cytoplasmic tail 35 amino acids longer than that of the wildtype LPA 2 , coupled to the XbaI site of the 6 Kb a-subunit of the mouse inhibin promoter (Kananen et al., 1995; Hsu et al., 1996) . Human LPA 2 TG mice were identified by slot blot and PCR analyses of tail-tissue genomic DNA (Laird et al., 1991) . PCR analyses were performed with 50 ml of red Taq PCR reaction mix (Sigma, St Louis, MO, USA), 10 pM primers and 1.5 U of Taq DNA polymerase. The human LPA 2 forward PCR primer was 5 0 -GCAATGTCCTGGCTGTAGAAA-3 0 and the reverse PCR primer was 5 0 -GTGGCCGTTCTCGGGAA-3 0 . Each of the 35 PCR cycles, followed by the initial denaturation at 941C for 3 min, included denaturation at 941C for 30 s, annealing at 571C for 30 s and extension at 721C for 30 s. Slot-blot assays were performed by hybridizing 2 mg of tail genomic DNA with a human PCRgenerated LPA 2 probe.
Taqman real time RT-PCR
Intact ovaries were removed from TG and wild-type mice and flash-frozen on dry ice for extraction of total ovarian RNA by homogenization and treatment with Tri-reagent (Molecular Research Center, Cincinnati, OH, USA). Each sample of RNA was treated with RNase-free DNase I (Qiagen, Valencia, CA, USA) for 30 min at room temperature before isolation (RNeasy Kit, Qiagen 0 . The primers and probes for mouse VEGF-A, VEGF-B, VEGF R1 (flt-1) and VEGF R2 (flk-1) are described elsewhere (Gerber et al., 2000) . PCR analyses of VEGF-A isoforms all employed the same forward primer and probe but the reverse primers were different in order to discriminate between VEGF 120 , VEGF 144 , VEGF 164 , VEGF 188 and VEGF 205 (Zhang et al., 2002) . For mouse uPA , the forward primer is 5 0 -TGCTATCATGGAAATGGT-GACTCTT-3 0 , reverse 5 0 -GGGCATTGTAGGGTTTCT-GAAG-3 0 , and probe 5 0 -FAM-ACACTGAT-ACCAAAGG-TCGGCCCTGC-TAMRA-3 0 ; mouse tPA (tissue type plasminogen activator), forward primer is 5 0 -GTGGAATATTGCC-GGTGCA-3 0 , reverse 5 0 -GTCCCCCCATTGAAGCATCT-3 0 , and probe 5 0 -FAM-CGGCCTGGTACAATGC-CACTCAG-TG-TAMRA-3 0 ; mouse uPAR, forward primer is 5 0 -CGGGA-ATGGCA-AGATGATAGA-3 0 , reverse 5 0 -ACACGGTCTC-TGTCAGGCTGA-3 0 , and probe 5 0 -FAM-TGAGTTACCG-CATGGGCTCCATGATC -TAMRA-3 0 ; mouse PAI-1, forward primer is 5 0 -CAGAGCAACAAGTTCAACTACAC-TGA-3 0 , reverse 5 0 -CAG-CGATGAACATGCTGAGG-3 0 , and probe 5 0 -FAM-ATGACGTCGTGGAACTGCC-CTAC-CA-TAMRA-3 0 ; mouse PAI-2, forward primer is 5 0 -CCGCA-TACTGGAAAC-ATCAGC-3 0 , reverse 5 0 -AAGCCAGTGG-ATGCGTCCT-3 0 , and probe 5 0 -FAM-TG-CTCCTGTTGCT-TCCCGATGAGATT-TAMRA-3 0 . Taqman reagents for internal standards were: rodent GAPDH, forward 5 0 -TGCAC-CACCAACTGCTTAG-3 0 , reverse 5 0 -GGATGCAGGGAT-GATGTTC -3 0 , and probe 5 0 -TET-CAGAAGACTG-TGGA-TGGCCCCTC-TAMRA-3 0 ; mouse HPRT-forward 5 0 -CTG-GTGAAAAGGA-CCTCTCG -3 0 , reverse 5 0 -TGAAGTACT-CATTATAGTCAAGGGCA-3 0 , and probe 5 0 -TET-TGTT-GGATACAGGCCAGACTTTGTTGGA-TAMRA-3 0 , and human HPRT, forward 5 0 -GGCAGTATAATCCAAAGAT-GGTCAA -3 0 , reverse 5 0 -GTCTG-GCTTATATCCAACACT-TCGT-3 0 , and probe 5 0 -TET-CAAGCTTGCTGGTGAAA-AGGACCCC-TAMRA-3 0 .
Ovarian protein extraction
Proteins in the phenol-ethanol extract of homogenized ovaries were precipitated by isopropanol, followed by washing three times with 0.3 m guanidine hydrochloride in 95% ethanol and once with 100% ethanol (Tri-reagent, MRC). Precipitated proteins were solubilized in 1 Â PBS with 1% Nonidet P-40, 0.5% sodium deoxycholate and 0.1% SDS with 5 mm tributylphosphine (Sigma, St Louis, MO, USA) and their concentrations were determined by the BCA method (Pierce, Rockford, IL, USA).
Ovarian cell culture, uPA activity assay and VEGF ELISA Whole ovaries were cut into 1-2 mm cubes and cultured ex vivo in DMEM containing 4.5 g glucose/l, 0.548 g l-glutamine/l, 0.11 mg sodium pyruvate/ml, 10% fetal bovine serum (FBS) and penicillin-streptomycin at 10 mg of tissue/ml. Replicate samples of cultured ovarian explants were deprived of serum lipids for at least 4 h in DMEM with 5% (V : V) charcoaladsorbed FCS with and without LPA (Avanti polar lipids, Alabaster, AL, USA). Conditioned media from ovarian explants were collected, centrifuged and assayed within 48 h. The kit for quantification of uPA activity (Chemicon, Inc., Temecula, CA, USA) and that for measurement of VEGF protein (R& D systems, Minneapolis, MN, USA) were used according to the suppliers' guidelines.
Western immunoblotting
Ovarian proteins (5 mg) were electrophoresed in each lane of an SDS-12.5% polyacrylamide gel for 90 min at 100 V. Resolved proteins were transfered electrophoretically to a polyvinylidene difluoride membrane (BioRad, Hercules, CA, USA), incubated with 0.5 mg/ml of mouse monoclonal antibody to an aminoterminal peptide (amino acids 9-27) of human LPA 2 R or polyclonal rabbit antibody to VEGF (Oncogene, San Diego, CA, USA) for 1 h, and then detected with 1/5000 horseradish peroxidase-labeled anti-mouse IgG for human LPA 2 R and goat anti-rabbit IgG for VEGF and ECL luminescence (Amersham Pharmacia Biotech, Arlington Heights, IL, USA).
Immunohistochemistry
Ovaries from wild-type and TG mice were fixed with fresh 4% paraformaldehyde for 4 h at room temperature, cryoprotected with 30% sucrose in 0.1 m sodium phosphate buffer (pH 7.3), frozen, and cut by cryostat into 5 mm thick sections, which were mounted on Superfrost/Plus slides (Fisher Scientific, Pittsburgh, PA, USA). Hematoxylin and eosin staining was used for structural orientation and identification. Selected frozen sections were brought to room temperature, washed twice for 5 min each in PBS, and incubated in 3% hydrogen peroxide in methanol for 30 min to block endogenous peroxidases, incubated sequentially with 0.3% Triton X-100 and 10% normal goat serum/1% BSA in 0.05 m sodium phosphate/Tris-buffered saline (IHC buffer) (pH 7.3) for 2 h, and then incubated with 20-200 ng/ml of anti-LPA 2 or anti-VEGF antibodies at 41C overnight. Immunostaining was detected with the respective biotinylated second antibodies, avidin-horse radish peroxidase complexes and a diaminobenzidine-peroxidase substrate solution.
